Format

Send to

Choose Destination
EMBO Mol Med. 2014 Nov;6(11):1359-70. doi: 10.15252/emmm.201302627.

Emerging treatment strategies for glioblastoma multiforme.

Author information

1
Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation University of Miami Miller School of Medicine, Miami, FL, USA.
2
Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation University of Miami Miller School of Medicine, Miami, FL, USA cwahlestedt@med.miami.edu.

Abstract

Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5-year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small-molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population.

KEYWORDS:

biomarkers; brain imaging; cancer stem cells; epigenetics; glioblastoma multiforme (GBM)

PMID:
25312641
PMCID:
PMC4237465
DOI:
10.15252/emmm.201302627
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center